.jpg)
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Human medicines European public assessment report (EPAR): Stelara, ustekinumab, ...
In this tracker, Fierce Pharma is recording the regulatory progress of in-market...
As always, if you know of layoffs occurring at a biotech, please reach out to th...
Ten of 11 children born with a rare form of congenital hearing loss experienced ...
Eli Lilly will offer more doses of its obesity drug Zepbound in vials and lower ...
Human medicines European public assessment report (EPAR): Brimica Genuair, aclid...
Human medicines European public assessment report (EPAR): Eptifibatide Accord, e...
With Lava Therapeutics still smoldering from the decision to dump its lead blood...
While some NIH study sections will resume, advisory council meetings, which make...
Human medicines European public assessment report (EPAR): Bretaris Genuair, acli...
Human medicines European public assessment report (EPAR): Trumenba, meningococca...
Human medicines European public assessment report (EPAR): Seladelpar Gilead, Sel...
The Trump administration’s plans to reduce National Institutes of Health grant f...
Takeda has returned to BridGene Biosciences for another small-molecule collabora...
For the last six weeks the shadow of potential layoffs has hung over Repare Ther...
Human medicines European public assessment report (EPAR): Tacforius, tacrolimus,...
Questions and answers for biological medicinal products
Human medicines European public assessment report (EPAR): Pregabalin Pfizer, pre...
Human medicines European public assessment report (EPAR): Carvykti, ciltacabtage...
Eli Lilly said Tuesday that it will offer more doses of its obesity drug Zepboun...
As Alcon Research seeks to block investee Aurion Biotech from listing on the New...
BioCity Biopharma’s selective endothelin receptor type A antagonist has reduced ...
Herbal medicinal product: Tribuli terrestris herbaArray, D: Draft under discussion